Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 and type 1 diabetes have opposing effects on the systemic murine complement alternative pathway.

iScience·2026
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Cancer immunology research·2026
Same author

Insights and perspectives into the discovery of complement-related biomarkers in cancer.

Current opinion in immunology·2025
Same author

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.

Signal transduction and targeted therapy·2025
Same author

Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8-Driven Inflammation in COVID-19.

Immunology·2025
Same journal

Myeloid cells as sources and targets of IL-1 family cytokines in cancer.

Seminars in immunology·2026
Same journal

Interleukin-1-mediated inflammatory memory: Protective training or maladaptive tumor imprinting?

Seminars in immunology·2026
Same journal

Chronic stress at the crossroads: Decoding the HPA-SAM-immune-gut axis in inflammatory bowel disease pathogenesis and therapeutics.

Seminars in immunology·2026
Same journal

Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity.

Seminars in immunology·2026
Same journal

The immune system in Latin America and the Caribbean: Insights into diseases and diversity from local perspectives.

Seminars in immunology·2026
Same journal

Introduction to the special issue: T<sub>H</sub>9 cells in diseases.

Seminars in immunology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Complement inhibition in cancer therapy.

Ruben Pio1, Daniel Ajona, John D Lambris

  • 1Oncology Division, Center for Applied Medical Research-CIMA, Pamplona, Spain. rpio.@unav.es

Seminars in Immunology
|May 28, 2013
PubMed
Summary
This summary is machine-generated.

Complement traditionally aids tumor cell destruction but can paradoxically promote cancer. Inhibiting complement activation offers a novel therapeutic strategy against tumors by blocking its pro-cancer effects.

Keywords:
AMDAngiogenesisC1 inhibitorC1-INHCancer therapyComplement systemImmunosuppressionInflammationMACMDSCTGF-βTLRTregsTumor microenvironmentage-related macular degenerationmembrane attack complexmyeloid-derived suppressor cellsregulatory T cellstoll-like receptortransforming growth factor β

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: May 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

  • Immunology
  • Oncology
  • Complement System

Background:

  • Complement system traditionally viewed as a tumor cell effector arm.
  • Therapeutic strategies have focused on enhancing complement-mediated anti-tumor responses.
  • Emerging evidence reveals a tumor-promoting role for the complement system in cancer.

Purpose of the Study:

  • To summarize complement activation mechanisms on cancer cells.
  • To elucidate the cancer-promoting effects of complement initiation.
  • To present the rationale for using complement inhibition as a cancer therapy.

Main Methods:

  • Review of existing literature on complement activation in cancer.
  • Analysis of studies demonstrating complement's pro-tumorigenic functions.
  • Synthesis of evidence supporting complement inhibition as a therapeutic strategy.

Main Results:

  • Cancer cells can exploit complement activation for their benefit.
  • Complement promotes tumor growth via inflammation, immunosuppression, and angiogenesis.
  • Complement activation can drive cancer-related signaling pathways.

Conclusions:

  • The role of complement in cancer is complex and can be tumor-promoting.
  • Inhibition of complement activation presents a promising new therapeutic avenue for cancer treatment.
  • Further research into complement's dual role is crucial for developing effective cancer therapies.